株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肺癌治療薬:世界市場

Lung Cancer Therapeutics: Global Markets

発行 BCC Research 商品コード 746168
出版日 ページ情報 英文 161 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.99円で換算しております。
Back to Top
肺癌治療薬:世界市場 Lung Cancer Therapeutics: Global Markets
出版日: 2018年11月14日 ページ情報: 英文 161 Pages
概要

世界の肺癌治療薬市場は2018年の179億米ドルからCAGR8.0%で拡大し、2023年には263億米ドルになると予測されています。

当レポートでは、世界の肺癌治療薬市場について調査し、市場の概要と概要、地域別動向、市場に参入する主要企業のプロファイルなどについてまとめています。

第1章 イントロダクション

第2章 サマリーおよびハイライト

第3章 概要

  • イントロダクション
  • 肺癌のタイプ
  • 肺癌の病期
  • リスクファクター
  • 肺癌の症状
  • 肺癌の診断
  • 肺癌の管理

第4章 市場動向

  • 市場促進因子
  • 市場阻害因子
  • 市場の機会
  • 治験の失敗

第5章 肺癌タイプ別市場内訳

  • 市場概要
  • 市場規模と予測
    • 非小細胞肺癌
    • 小細胞肺癌

第6章 地域別市場内訳

  • 肺癌の疫学
  • 地域別世界の肺癌治療薬市場
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第7章 償還動向

  • イントロダクション
  • 米国
  • ドイツ
  • ブラジル
  • 中国

第8章 特許動向

第9章 法規制動向

第10章 競合環境

第10章 企業プロファイル

第11章 パイプライン分析

第12章 企業プロファイル

第13章 略語

図表

List of Tables

  • Summary Table: Global Market for Lung Cancer Therapeutics, by Type, Through 2023
    • Table 1: TNM Classification of Malignant Tumors of Lung Cancer
    • Table 2: Five-Year Survival Rates, NSCLC and SCLC
    • Table 3: Targeted Therapy for Lung Cancer
    • Table 4: Targeted Antibodies Used in Lung Cancer
    • Table 5: Immunomodulators Used in Lung Cancer
    • Table 6: CAR T-Cell Therapy Clinical Trials Under Investigation
    • Table 7: Comparison of Overall Estimated Number of New Cancer Cases, by Type, 2018
    • Table 8: Age-Standardized Lung Cancer Incidence Rate, Rankings by Country, 2017
    • Table 9: Age-Standardized Lung Cancer Incidence Rate in Men, Rankings by Country, 2017
    • Table 10: Age-Standardized Lung Cancer Incidence Rate in Women, Ranking by Country, 2017
    • Table 11: Lung Cancer Incidence in Key Countries, 2017
    • Table 12: Proportion of Daily Cigarette Smokers in Europe, by Gender, 2014
    • Table 13: Patent Expiration of Lung Cancer Drugs
    • Table 14: Incidence of Lung Cancer in Asia-Pacific, 2016
    • Table 15: Prominent Drugs to Treat Lung Cancer
    • Table 16: Global Market for Lung Cancer Therapeutics, by Type, Through 2023
    • Table 17: Global Market for Lung Cancer Therapeutics, by Region, Through 2023
    • Table 18: Estimated Lung Cancer Statistics for Canada, 2017
    • Table 19: Lung Cancer Incidence in Canada, Male and Female
    • Table 20: Overall Healthcare Expenditures in Europe, by Country, Through 2015
    • Table 21: Number of New Lung Cancer Cases in the U.K., by Gender, 2015
    • Table 22: Medicare Part B: Lung Cancer Drug Payment Limits, 2018
    • Table 23: Lung Cancer Drug Reimbursement in Germany, 2018
    • Table 24: Oncology Drugs Covered by China's National Insurance
    • Table 25: U.S. Patents on Lung Cancer Therapeutics, 2001-2018
    • Table 26: Patent Expiration of Lung Cancer Drugs
    • Table 27: List of FDA-Approved Drugs, Through 2018
    • Table 28: Lung Cancer Drugs Approved by Health Canada, Through 2018
    • Table 29: NSCLC Drugs Authorized by the EMA, Through 2018
    • Table 30: NSCLC Drugs Pending Approval by the EMA, Through 2018
    • Table 31: NSCLC Drugs Withdrawn by the EMA, Through 2018
    • Table 32: NSCLC Drugs Pending Application Withdrawal by the EMA, Through 2018
    • Table 33: SCLC Drugs Pending Withdrawal by the EMA, Through 2018
    • Table 34: Global Ranking of Lung Cancer Drug Companies, 2017
    • Table 35: Eli Lilly and Co.: Lung Cancer Marketed Products and Investigational Molecules, Through 2018
    • Table 36: AstraZeneca Pharmaceuticals: Lung Cancer Marketed Products and Investigational Molecules, Through 2018
    • Table 37: Lung Cancer Pipeline Drugs, Through 2018
    • Table 38: Clinical Efficacy of Select Third-Generation EGFR TKIs in Clinical Development
    • Table 39: AbbVie Inc.: Net Revenue, 2015-2017
    • Table 40: AbbVie Inc.: Lung Cancer Pipeline
    • Table 41: Astellas Pharma Inc.: Net Revenue, 2013-2017
    • Table 42: Astellas Pharma Inc.: Net Revenue, by Country/Region, 2014-2017
    • Table 43: AstraZeneca Plc: Net Revenue, 2014-2017
    • Table 44: AstraZeneca Plc: Marketed Products, 2018
    • Table 45: Bayer AG: Net Revenue, 2015-2017
    • Table 46: Bayer AG: Lung Cancer Pipeline Molecules
    • Table 47: Boehringer Ingelheim GmbH: Net Revenue, 2014-2016
    • Table 48: Boehringer Ingelheim GmbH: Marketed Product, 2018
    • Table 49: Bristol-Myers Squibb: Net Revenue, 2014-2016
    • Table 50: Bristol-Myers Squibb: Marketed Products, 2018
    • Table 51: Celgene Corp.: Net Revenue, 2015-2016
    • Table 52: Daiichi Sankyo Co., Ltd.: Net Revenue, 2015-2017
    • Table 53: Eli Lilly and Co.: Net Revenue, 2014-2017
    • Table 54: Eli Lilly and Co.: Net Revenue, by Segment, 2014-2016
    • Table 55: Eli Lilly and Co.: Net Revenue, by Oncology Drug, 2014-2016
    • Table 56: F. Hoffmann-La Roche Ltd.: Net Revenue, by Segment, Through 2017
    • Table 57: Tarceva: Drug Revenue, by Country/Region, 2016-2017
    • Table 58: Merck & Co., Inc.: Net Revenue, 2014-2016
    • Table 59: Novartis International AG: Net Revenue, by Segment, Through 2017
    • Table 60: Novartis International AG: Oncology Drugs Revenue, 2015-2017
    • Table 61: Pfizer Inc.: Net Revenue, 2014-2017
    • Table 62: Pfizer Inc.: Oncology Drug Revenue, 2015-2017
    • Table 63: Pfizer Inc.: Oncology Drugs Revenue, 2015-2017
    • Table 64: Pfizer Inc.: Lung Cancer Marketed Products and Investigational Drug Candidates, 2018
    • Table 65: Acronyms Used in Global Lung Cancer Therapeutics Market

List of Figures

  • Summary Figure: Global Market for Lung Cancer Therapeutics, by Type, 2017-2023
    • Figure 1: Gross Anatomy of the Human Lung
    • Figure 2: Share of Lung Cancer Types, by Histology
    • Figure 3: National Cancer Institute Research Funding, 2011-2016
    • Figure 4: U.S. Smoking Statistics, by Gender, 2017
    • Figure 5: Percentage Share of Lung Cancer Incidence, by Type of Mutation
    • Figure 6: Global Market for Non-Small Cell Lung Cancer Therapeutics, 2017-2023
    • Figure 7: Global Market for Small Cell Lung Cancer Therapeutics, 2017-2023
    • Figure 8: Percentage Share of Global Lung Cancer Incidence, by Country/Region, 2018
    • Figure 9: North American Market for Lung Cancer Therapeutics, 2017-2023
    • Figure 10: Percentage Share of Estimated Cancer Incidence in North America, by Type, 2018
    • Figure 11: Percentage Share of Estimated Cancer Incidence in the United States, by Type, 2018
    • Figure 12: European Market for Lung Cancer Therapeutics, 2017-2023
    • Figure 13: Per Capita Spending on Market Sectors in Europe, 2015
    • Figure 14: Incidence Rates of Lung Cancer in the U.K., by Gender, 1993-2015
    • Figure 15: Incidence of Lung Cancer in Scotland, by Cancer Stage, 2014-2015
    • Figure 16: Incidence of Lung Cancer in Italy, by Gender, 2010 and 2015
    • Figure 17: Percentage Share of Estimated Cancer Incidence in France, by Type, 2018
    • Figure 18: Percentage Share of Estimated Cancer Incidence in Germany, by Type, 2018
    • Figure 19: Asia-Pacific Market for Lung Cancer Therapeutics, 2017-2023
    • Figure 20: Percentage Share of Estimated Cancer Incidence in Asia-Pacific, by Type, 2018
    • Figure 21: Estimated Cancer Incidence in Asia-Pacific, by Country, 2018
    • Figure 22: Middle East and African Market for Lung Cancer Therapeutics, 2017-2023
    • Figure 23: Percentage Share of Estimated Cancer Incidence in Africa, by Type, 2018
    • Figure 24: South American Market for Lung Cancer Therapeutics, 2017-2023
    • Figure 25: Percentage Share of Estimated Cancer Incidence in South America, by Type, 2018
    • Figure 26: Drug Reimbursement Scenerio in Germany
    • Figure 27: Federal and Inter-Provincial Approval System for Cancer Drugs in Canada
    • Figure 28: Medical Device PMDA Approval Procedure
    • Figure 29: AbbVie Inc.: Revenue Share, by Region, 2016
    • Figure 30: Erlotinib: Revenue, 2015-2016
    • Figure 31: AstraZeneca Plc: Financial Performance, 2015-2017
    • Figure 32: AstraZeneca Plc: Financial Performance, 2013-2017
    • Figure 33: AstraZeneca Plc: Revenue Share, by Business Unit, 2017
    • Figure 34: AstraZeneca Plc: Revenue Share, by Country/Region, 2017
    • Figure 35: Bayer AG: Revenue Share, by Region, 2017
    • Figure 36: Bayer AG: Revenue Share, by Region, 2017
    • Figure 37: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2016
    • Figure 38: Boehringer Ingelheim GmbH: Revenue Share, by Business Segment, 2016
    • Figure 39: Boehringer Ingelheim GmbH: Research and Development Expenditures, 2014-2016
    • Figure 40: Bristol-Myers Squibb: Revenue Share, by Country/Region, 2016
    • Figure 41: Bristol-Myers Squibb: Revenue Share, by Business Segment, 2016
    • Figure 42: Abraxane: Revenue, 2015-2017
    • Figure 43: Daiichi Sankyo Co., Ltd.: Revenue Share, by Business Segment, 2016
    • Figure 44: Eli Lilly and Co.: Revenue Share, by Country/Region, 2016
    • Figure 45: F. Hoffmann-La Roche Ltd.: Pharmaceuticals Revenue Share, by Business Segment, 2016
    • Figure 46: F. Hoffmann-La Roche Ltd.: Lung Cancer Drug Revenue, 2016-2017
    • Figure 47: Merck & Co., Inc.: Revenue Share, by Business Segment, 2016
    • Figure 48: Merck & Co., Inc.: Keytruda Revenue, 2015-2017
    • Figure 49: Merck & Co., Inc.: Revenue Share, by Region, 2016
    • Figure 50: Pfizer Inc.: Revenue Share, by Region, 2016
    • Figure 51: Pfizer Inc.: Revenue Share, by Business Segment, 2016
目次
Product Code: PHM206A

Report Highlights:

The global market for lung cancer therapeutics should grow from $17.9 billion in 2018 to $26.3 billion by 2023, increasing at a compound annual growth rate (CAGR) of 8.0% from 2018 to 2023.

The global market for non-small cell lung cancer (NSCLC) should grow from $16.1 billion in 2018 to $23.5 billion by 2023, increasing at a CAGR of 7.9% from 2018 to 2023.

The global market for small cell lung cancer (SCLC) should grow from $1.8 billion in 2018 to $2.8 billion by 2023, increasing at a CAGR of 9.1% from 2018 to 2023.

Report Scope:

This report provides a detailed analysis of prevailing lung cancer treatment guidelines in different geographic regions. This report looks at lung cancer therapeutics market revenue by disease type (i.e., NSCLC and SCLC) and the proportion of chemotherapeutics and targeted therapies used for treating each disease type in different geographic regions. Non-pharmaceutical treatment segments like radiation and surgery are excluded from this report. Lung cancer therapeutic market data is present for 2017 and for the forecast period, which is 2018 to 2023. The market data provided in this report are based on manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Detailed lung cancer therapeutic market analyses are presented for five regions: North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.

Global market drivers, trends and challenges affecting the lung cancer therapeutics market are presented in this report. Detailed analyses of the competitive environments, pipeline analysis, patents, regulatory landscape and reimbursement landscape are included in the report.

Report Includes:

  • 34 data tables and 32 additional tables
  • An in-depth overview of the global market for lung cancer therapeutics within the industry
  • Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Identification of key market dynamics, trends, opportunities and factors influencing the global lung cancer drug technology
  • Assessment of major regulatory pathways and hurdles faced by lung cancer therapeutic product manufacturers
  • Information pertaining to lung cancer drug patent applications, expirations and the latest key technology developments, pipeline analysis, reimbursement scenarios, and unmet needs associated with the market
  • Dossier of mergers and acquisitions, new product development, strategies, research and development activities of major market players
  • Examination of competitive landscape for the lung cancer therapeutics market, and information pertaining to leading lung cancer market players, their marketed products, pipeline products and product patent expirations
  • Detailed company profiles of major manufacturers of oncology products, including Bayer AG, Bristol-Myers Squibb Co., Daiichi Sankyo Co., Ltd., Novartis International AG and Pfizer Inc.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Introduction
  • Lung Cancer Types
    • In Situ Lung Cancer
    • Malignant Lung Tumors
  • Stages of Lung Cancer
    • Staging of NSCLC
    • Staging of SCLC
  • Risk Factors
    • Tobacco Smoking
    • Second-Hand Smoking (SHS)
    • Exposure to Asbestos
    • Exposure to Other Elements
    • Family History
    • Personal History
  • Lung Cancer Symptoms
    • Symptoms of Tumor Growth in the Lungs and Chest
    • Symptoms Caused by Metastases Beyond the Chest
    • Symptoms Caused by Tumor Secretion
  • Lung Cancer Diagnosis
    • General Screening Tests
  • Lung Cancer Management
    • Radiation Therapy
    • Chemotherapy
    • Surgery
    • Targeted Therapy for Lung Cancer
    • Immunotherapy for Lung Cancer
    • Palliative Treatment for Lung Cancer

Chapter 4: Market Dynamics

  • Market Drivers
    • Global Increase in Lung Cancer Incidence
    • Increase in Healthcare Expenditures and Government Funding in Key Countries
    • Robust Clinical Drug Pipeline
    • Increasing Life Expectancy of Lung Cancer Patients
    • Surge in Female Smokers
  • Market Restraints
    • Patent Expiration of Key Drug Molecules
    • Regulatory and Reimbursement Hurdles
    • Available Low-Priced Chemotherapeutics Limiting Growth of Advanced Therapies
  • Market Opportunities
    • Highest Incidence of Lung Cancer in Asia-Pacific
    • Increasing Demand for Targeted Therapies (EGFR or ALK Inhibitors, TKIs)
    • Increasing Incidence of NSCLC and its Non-responsiveness to Chemotherapy
    • Increasing Lung Cancer Incidence Among Non-Smokers
  • Clinical Trial Failures

Chapter 5: Market Breakdown by Lung Cancer Type

  • Market Overview
  • Market Size and Forecast
    • Non-Small Cell Lung Cancer
    • Small Cell Lung Cancer

Chapter 6: Market Breakdown by Region

  • Epidemiology of Lung Cancer
  • Global Market for Lung Cancer Therapeutics by Region
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America

Chapter 7: Reimbursement Landscape

  • Introduction
  • United States
    • Lung Cancer Drug Reimbursement
  • Germany
    • Lung Cancer Drug Reimbursement
  • Brazil
  • China

Chapter 8: Patent Review

  • Patents Granted
  • Patent Expiration

Chapter 9: Regulatory Landscape

  • Regulatory Challenges for Lung Cancer Therapeutics
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Mutual Recognition Procedure
    • Decentralized Procedure
    • Centralized Procedure
  • Asia-Pacific
    • Japan
    • China
    • India
    • South Korea
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
  • South America
    • Brazil
    • Argentina

Chapter 10: Competitive Landscape

  • Major Lung Cancer Drug Companies
    • Eli Lilly and Co.
    • AstraZeneca Pharmaceuticals
    • Pfizer Inc.

Chapter 11: Pipeline Analysis

  • Introduction
    • Late-Stage Pipeline Drug Candidates
    • JAK Inhibitors for Lung Cancer
    • Third-Generation EGFR TKIs

Chapter 12: Company Profiles

  • ABBVIE INC.
    • Company Overview
    • Financials
    • Product Information
    • Development and Strategies
  • AMGEN INC.
    • Company Overview
  • ASTELLAS PHARMA INC.
    • Financials
  • ASTRAZENECA PLC
    • Company Overview
    • Financials
    • Products and Services
    • Developments and Strategies
  • BAYER AG
    • Company Overview
    • Financials
    • Product Information
  • BETA PHARMA INC.
    • Business Overview
    • Products and Services
  • BOEHRINGER INGELHEIM GMBH
    • Company Overview
    • Financials
    • Products and Services
    • Development and Strategies
  • BRISTOL-MYERS SQUIBB CO.
    • Company Overview
    • Financials
    • Products and Services
  • CELGENE CORP.
    • Company Overview
    • Financials
    • Products and Services
  • DAIICHI SANKYO CO., LTD.
    • Company Overview
    • Financials
    • Product and Services
  • ELI LILLY AND CO.
    • Company Overview
    • Financials
  • F. HOFFMANN-LA ROCHE AG
    • Company Overview
    • Financials
    • Products and Services
  • MERCK & CO., INC.
    • Company Overview
    • Financials
    • Products and Services
    • Development and Strategies
  • NOVARTIS INTERNATIONAL AG
    • Company Overview
    • Financials
    • Products and Services
    • Development and Strategies
  • PFIZER INC.
    • Company Overview
    • Financials
    • Product Information
    • Development and Strategies
  • TAKEDA PHARMACEUTICALS CO.
    • Company Overview

Chapter 13: Appendix: Acronyms

Back to Top